Document is current
Any future updates will be listed below
-
Authors
McGeagh, Lucy https://orcid.org/0000-0002-9226-5115
Walker, Alice
Hiller, Louise
Dunn, Janet
Wells, Mary
Donnelly, Peter
Wardley, Andrew
Wolstenholme, Jane
Horne, Robert
Stewart, Sarah-Jane
Brett, Jo
Cahir, Caitriona
Fenlon, Deborah
Rose, Jan
Turner, Lesley
Hughes, Lyndsay
Todd, Adam
Nicholson, Brian
Mawson, Phil
Norris, Ruth
Thompson, Sue
Dakin, Helen
Barrows, Raegan
Kum, Sally
Turner, Mark
Rehman, Farah
Cain, Henry
Watson, Eila
Sharp, Linda
,
King, Alex
Harmer, Victoria
Levitt, Nicky
Mann, Anna
McCowan, Colin
Moon, Zoe
Porteous, Mia
Smith, Samuel G.
-
Funding
Funding for this research was provided by:
National Institute for Health and Care Research (NIHR200098)
- License Information
-
More Information
Article History
Received: 13 September 2024
Accepted: 10 August 2025
First Online: 26 November 2025
Declarations
:
: Ethical approval was provided by South Central - Hampshire B Research Ethics Committee 11.08.2023. Written, informed consent to participate will be obtained from all participants.
: Not applicable—details, images, or videos relating to an individual person are not included.
: All authors have declared no competing interests, with the exception of the following:FR discloses honoraria from Pfizer and Astra Zeneca/Daiichi Sankyo.HC reports Roche Medical. Ad Board, support with Travel, Honorarium for speaking, Research Grant.; Astra Zeneca. Ad Board, Honorarium for speaking; Exact Health. Honorarium for speaking, Ad board, Research grant; Pfizer. Honorarium for speaking; Baxter. Honorarium for speaking, Ad Board; Lilly. Ad Board; Veracyte. Ad board; Allergan. Speaking and meeting support; MSD. Honorarium for speaking and Ad Board and Novartis. Ad Board.RH reports speaker engagement with honoraria for AbbVie, Abbott, Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Biogen, Gilead Sciences, GlaxoSmithKline, Janssen, Merck Sharp Dohme, Merck, Novartis, Pfizer, Procter & Gamble, Roche, Sanofi, Shire Pharmaceuticals, TEVA, UCB, personal consultancy for Amgen, Abbott, AstraZeneca and Novartis. He is the Founding Director of a UCL-Business company (Spoonful of Sugar Ltd) providing consultancy on treatment engagement and patient support programmes to healthcare policy makers, providers and pharmaceutical industry.SH works for Breast Cancer Now (who are providing nurse support for the RCT).SS reports personal consultancy to Lilly.VH has received travel grants from TiLoop, speaker fee from Digistain limited and Roche, consultancy fee from Medscape, Novartis, Gilead and Bioderma and has been a nurse rep for OPTIMA.ZM reports paid work for UCL Business Company Spoonful of Sugar Ltd.No other relationships or activities have been declared that could appear to have influenced the submitted work.
